Blood coagulation factor Xa as an emerging drug target

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 3, 2011, Pages 341-349

  Borensztajn, Keren ^a   Spek, C Arnold ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Blood coagulation; Factor Xa; Fibrosis; Protease activated receptor

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLOOD CLOTTING; CYTOLOGY; DRUG TARGETING; DRUG WITHDRAWAL; FIBROSIS; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DRUG DELIVERY SYSTEMS; FACTOR XA; FIBROSIS; HUMANS; RECEPTOR, PAR-1; RECEPTOR, PAR-2; SIGNAL TRANSDUCTION; THROMBIN;

EID: 79951622301     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.553608     Document Type: Review

References (88)

1. Lippi G, Favaloro EJ, Franchini M, et al. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 2009;35:9-22
2. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988;53:505-18
3. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-9
4. Adams RL, Bird RJ. Review article: coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants. Nephrology (Carlton) 2009;14:462-70
5. Pinto DJ, Smallheer JM, Cheney DL, et al. Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem 2010;53:6243-74
6. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5(Suppl 1):60-4
7. Zikria J, Ansell J. Oral anticoagulation with Factor Xa and thrombin inhibitors: is there an alternative to warfarin? Discov Med 2009;8:196-203
8. Zikria JC, Ansell J. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. Curr Opin Hematol 2009;16:347-56
9. Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005;35(Suppl 1):12-20 (Pubitemid 40343876)
10. Walenga JM, Jeske WP, Hoppensteadt D, et al. Factor Xa inhibitors: today and beyond. Curr Opin Investig Drugs 2003;4:272-81 (Pubitemid 36534454)
11. Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008;17:1937-45
12. Sinha U, Ku P, Malinowski J, et al. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur J Pharmacol 2000;395:51-9 (Pubitemid 30227342)
13. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7- oxo- 6-(4-(2-oxopiperidin-1-yl)phenyl)- 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-56 (Pubitemid 350057846)
14. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6:820-9 (Pubitemid 351524543)
15. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504-14
16. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 2006;22:471-81
17. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939:an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005;3:2479-86 (Pubitemid 41727165)
18. Eriksson BI, Borris L, Dahl OE, et al. Direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-8
19. Cao YB, Zhang JD, Shen H, Jiang YY. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010;66:1099-108
20. Khorana AA. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost 2003;1:2463-5
21. Bouillaud S. De l'obliteration des veines et de son influence sur la formation des hydropisies partielles:considerations sur l'hydropisie passive et generale. Arch Gen Med 1823;1:188-204
22. Trousseau A. Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris 1865;3:654-712
23. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005;25:47-56 (Pubitemid 40054253)
24. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-64
25. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006;10:355-62 (Pubitemid 44693468)
26. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003;1:1495-503
27. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 2008;14:429-40
28. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-82 (Pubitemid 32476117)
29. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004;84:579-621 (Pubitemid 38365493)
30. Hanyaloglu AC, von Zastrow M. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol 2008;48:537-68 (Pubitemid 351738163)
31. Rauch BH, Millette E, Kenagy RD, et al. Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res 2004;94:340-5 (Pubitemid 38240725)
32. Al-Ani B, Hewett PW, Cudmore MJ, et al. Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. Hypertension 2010;55:689-97
33. Prager NA, Abendschein DR, McKenzie CR, et al. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995;92:962-7
34. Leadley RJ Jr, Chi L, Porcari AR. Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. Curr Opin Pharmacol 2001;1:169-75 (Pubitemid 33586408)
35. Barnard MR, Linden MD, Frelinger AL, et al. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005;3:2563-70 (Pubitemid 41727174)
36. Yamada T, Nagai Y. Immunohistochemical studies of human tissues with antibody to factor Xa. Histochem J 1996;28:73-7 (Pubitemid 26081912)
37. Yamazaki Y, Shikamoto Y, Fukudome K, et al. Fibroblasts, glial, and neuronal cells are involved in extravascular prothrombin activation. J Biochem (Tokyo) 1999;126:655-61
38. Shikamoto Y, Morita T. Expression of factor X in both the rat brain and cells of the central nervous system. FEBS Lett 1999;463:387-9 (Pubitemid 30001956)
39. Pejler G, Lunderius C, Tomasini-Johansson B. Macrophages synthesize factor X and secrete factor X/Xa-containing prothrombinase activity into the surrounding medium. Thromb Haemost 2000;84:429-35
40. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989;62:1062-6 (Pubitemid 20011490)
41. Wojtukiewicz MZ, Rucinska M, Zimnoch L, et al. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000;97:335-42 (Pubitemid 30089038)
42. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001;86:1416-20 (Pubitemid 34007513)
43. Scotton CJ, Krupiczojc MA, Konigshoff M, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009;119:2550-63
44. Hamill CE, Caudle WM, Richardson JR, et al. Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Mol Pharmacol 2007;72:653-64 (Pubitemid 47347300)
45. Nomura K, Liu N, Nagai K, et al. Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis. Lab Invest 2007;87:150-60
46. Shinagawa K, Martin JA, Ploplis VA, Castellino FJ. Coagulation factor Xa modulates airway remodeling in a murine model of asthma. Am J Respir Crit Care Med 2007;175:136-43 (Pubitemid 46115084)
47. Borissoff JI, Heeneman S, Kilinc E, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010;122:821-30
48. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-63 (Pubitemid 34619269)
49. Christen T, Verin V, Bochaton-Piallat M, et al. Mechanisms of neointima formation and remodeling in the porcine coronary artery. Circulation 2001;103:882-8 (Pubitemid 32163889)
50. Hao H, Gabbiani G, Camenzind E, et al. Phenotypic modulation of intima and media smooth muscle cells in fatal cases of coronary artery lesion. Arterioscler Thromb Vasc Biol 2006;26:326-32 (Pubitemid 43732195)
51. Shinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807-16 (Pubitemid 47339255)
52. Enestrom S, Druid H, Rammer L. Fibrin deposition in the kidney in post-ischaemic renal damage. Br J Exp Pathol 1988;69:387-94
53. Chambers RC. Role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J Suppl 2003;44:33s-35s (Pubitemid 37222060)
54. Geiser T. Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair? Swiss Med Wkly 2003;133:405-11 (Pubitemid 37163106)
55. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003;31:S213-20 (Pubitemid 36458170)
56. Howell DC, Goldsack NR, Marshall RP, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001;159:1383-95 (Pubitemid 32947968)
57. Abendschein DR, Yang LY, Chun J, et al. Prolonged procoagulant activity on overstretch-injured coronary arteries in pigs. J Thromb Haemost 2003;1:836-42
58. Erbel R, Haude M, Hopp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998;339:1672-8 (Pubitemid 28550692)
59. Bauters C, Lablanche JM, McFadden EP, et al. Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis. Circulation 1995;92:2473-9
60. Liu MW, Hearn JA, Luo JF, et al. Reduction of thrombus formation without inhibiting coagulation factors does not inhibit intimal hyperplasia after balloon injury in pig coronary arteries. Coron Artery Dis 1996;7:667-71 (Pubitemid 26397182)
61. Borensztajn K, Stiekema J, Nijmeijer S, et al. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol 2008;172:309-20 (Pubitemid 351282019)
62. Chambers RC, Laurent GJ. Coagulation cascade proteases and tissue fibrosis. Biochem Soc Trans 2002;30:194-200
63. Blanc-Brude OP, Archer F, Leoni P, et al. Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res 2005;304:16-27 (Pubitemid 40222073)
64. Bachli EB, Pech CM, Johnson KM, et al. Factor Xa and thrombin, but not factor VIIa, elicit specific cellular responses in dermal fibroblasts. J Thromb Haemost 2003;1:1935-44
65. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92 (Pubitemid 24333194)
66. Xiong J, Zhu Z, Liu J, et al. Role of protease activated receptor-2 expression in renal interstitial fibrosis model in mice. J Huazhong Univ Sci Technolog Med Sci 2005;25:523-6
67. Cederqvist K, Haglund C, Heikkila P, et al. High expression of pulmonary proteinase-activated receptor 2 in acute and chronic lung injury in preterm infants. Pediatr Res 2005;57:831-6 (Pubitemid 40727114)
68. Howell DC, Johns RH, Lasky JA, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005;166:1353-65 (Pubitemid 40586507)
69. Masamune A, Kikuta K, Satoh M, et al. Protease-activated receptor-2-mediated proliferation and collagen production of rat pancreatic stellate cells. J Pharmacol Exp Ther 2005;312:651-8 (Pubitemid 40189563)
70. Grandaliano G, Pontrelli P, Cerullo G, et al. Protease-activated receptor-2 expression in IgA nephropathy:a potential role in the pathogenesis of interstitial fibrosis. J Am Soc Nephrol 2003;14:2072-83 (Pubitemid 36909915)
71. Saito H, Kitamoto M, Kato K, et al. Tissue factor and factor V involvement in rat peritoneal fibrosis. Perit Dial Int 2009;29:340-51
72. Borensztajn K, Aberson H, Peppelenbosch MP, Spek CA. FXa-induced intracellular signaling links coagulation to neoangiogenesis:potential implications for fibrosis. Biochim Biophys Acta 2009;1793:798-805
73. Bretschneider E, Schror K. Cellular effects of factor Xa on vascular smooth muscle cells - inhibition by heparins? Semin Thromb Hemost 2001;27:489-93 (Pubitemid 32989373)
74. Kaiser B. DX-9065a, a direct inhibitor of factor Xa. Cardiovasc Drug Rev 2003;21:91-104
75. Koo BH, Kim DS. Factor Xa induces mitogenesis of vascular smooth muscle cells via autocrine production of epiregulin. J Biol Chem 2003;278:52578-86
76. Pakala R. Coagulation factor Xa synergistically interacts with serotonin in inducing vascular smooth muscle cell proliferation. Cardiovasc Radiat Med 2003;4:69-76 (Pubitemid 37324458)
77. Ragosta M, Gimple LW, Gertz SD, et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1994;89:1262-71 (Pubitemid 24076554)
78. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-50
79. Lyle EM, Fujita T, Conner MW, et al. Effect of inhibitors of factor Xa or platelet adhesion, heparin, and aspirin on platelet deposition in an atherosclerotic rabbit model of angioplasty injury. J Pharmacol Toxicol Methods 1995;33:53-61
80. Kopp CW, Holzenbein T, Steiner S, et al. Inhibition of restenosis by tissue factor pathway inhibitor:in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity. Blood 2004;103:1653-61 (Pubitemid 38268956)
81. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs:nonthrombotic effects of thrombin in vessel wall biology. Circ Res 2001;88:987-97 (Pubitemid 34137110)
82. Peng CY, Pan SL, Guh JH, et al. The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thromb Haemost 2004;92:1232-9
83. Wahlgren CM, Frebelius S, Swedenborg J. Inhibition of neointimal hyperplasia by a specific thrombin inhibitor. Scand Cardiovasc J 2004;38:16-21 (Pubitemid 38455869)
84. Ollivier V, Chabbat J, Herbert JM, et al. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000;20:1374-81 (Pubitemid 30262941)
85. Akahane K, Okamoto K, Kikuchi M, et al. Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats. Surgery 2001;130:809-18 (Pubitemid 33022388)
86. Hezi-Yamit A, Wong PW, Bien-Ly N, et al. Synergistic induction of tissue factor by coagulation factor Xa and TNF:evidence for involvement of negative regulatory signaling cascades. Proc Natl Acad Sci USA 2005;102:12077-82 (Pubitemid 41291131)
87. Payeli SK, Latini R, Gebhard C, et al. Prothrombotic gene expression profile in vascular smooth muscle cells of human saphenous vein, but not internal mammary artery. Arterioscler Thromb Vasc Biol 2008;28:705-10 (Pubitemid 351651327)
88. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006;113:722-31